The Nevada Department of Taxation recently announced that it will open up applications for marijuana cultivation and production licenses in many of state’s rural counties.
A limited number of licenses were given out after the state passed laws in 2013 that would lead to the retail sale of medical marijuana.
Those licenses went to businesses in Clark, Washoe and Nye counties and Carson City, leaving none for the other 13 counties.
But in the most recent session of the Nevada Legislature, lawmakers passed a marijuana omnibus bill aimed at letting pot-barren counties have marijuana establishments.
The new law allows the tax department to accept applications from counties with populations below 100,000 — everything outside of Clark and Washoe — so that all counties can have at least one marijuana production and cultivation facility.
The state will accept those applications from Jan. 2 to Jan. 16. The form for businesses to apply can be found on the tax department’s website.
Panel: Don’t expect feds to move
Meanwhile, more and more states have dipped their toes into legal marijuana, but don’t expect lawmakers in Washington D.C. to make progress on the issue anytime soon.
That has people in the marijuana industry and its supporters feeling more like they’re playing defense just to keep the status-quo going.
That was the sentiment recently from a panel of two marijuana lobbyists and two lawmakers, including Nevada Rep. Dina Titus, discussing what’s happening in terms of marijuana legislation during the last day of the sixth annual Marijuana Business Conference and Expo in Las Vegas.
“We were gaining momentum. But now that’s flipped and we’re more on the defensive,” said Titus, who is seen as one of the biggest cannabis supporters in Congress.
Twenty-nine states, plus Washington D.C., have legal medical marijuana, and eight of those states, including Nevada, have legalized recreational use.
Now, people are watching to see what happens with the federal law that has allowed those states to go mostly unimpeded into the cannabis market.
That law, called the Rohrabacher-Blumenhauer amendment, prevents the U.S. Department of Justice — now headed by noted marijuana opponent Jeff Sessions — from using federal funds to interfere with state medical marijuana programs or prosecute businesses that comply with state laws.
“That’s the only thing holding (Sessions) back,” said panelist Michael Liszewski, with The Enact Group, a marijuana lobbying and consulting firm.
Amendment date upcoming
The amendment is set to expire on Dec. 8, and its future is uncertain after a group of Congressional Republicans blocked it from being attached to the DOJ appropriations bill in September.
Rohrabacher, who was also on the panel, said Republican leadership in Congress promised him that it would be re-inserted into the bill.
Titus said she’s not so sure that will be the case.
“I am not as trusting as Mr. Rohrabacher about what the leadership says,” Titus said.
The problem, Titus said, is that Congress has only been able to pass marijuana laws as amendments rather than stand-alone legislation, meaning those protections have to be renewed with each Congress.
But with Sessions as attorney general, the panelists agreed that marijuana faces a significantly rougher road in Washington.
Rohrabacher said Sessions represents a segment of Americans that is stuck in the 1960s “Reefer Madness” craze who think that anyone who consumes marijuana is “going to grow their hair long and go fornicate in the park.”
But panelist Michael Correia, government affairs director for the National Cannabis Industry Association, said there is a general feeling of support for medical marijuana in Washington, even among Republicans.
Correia said his goal as a marijuana lobbyist is to maintain the Rohrabacher-Blumenauer amendment to ensure the status-quo.
“Hopefully we don’t go backwards,” he said.
Contact Colton Lochhead on Twitter at clochhead@reviewjournal.com or 702-383-4638.